Loading patent…
AssigneeTechnische Universtität Dresden
InventorsChristian Bökel, Thomas Weidemann
Estimating the term…
The present invention relates generally to methods and compositions for reducing Interleukin-4 or Interleukin-13 signaling, in particular to treat asthma and atopic dermatitis. The inventors have found that Rac/PAK mediated endocytosis of the ligand bound type I (IL-4R with the chains IL-4Ra and IL-2-Rg) and/or type II receptor (IL-13R with the chains IL-4Ra and IL-13Ra1) is needed for the IL-4 and/or IL-13 mediated activation of downstream signalling events including phosphorylation of Stat family transcrition factors. These discoveries enable new methods of screening compounds that modulate Interleukin-4 and Interleukin-13 signalling, as well as new methods for treating conditions characterized by increased Interleukin-4 and Interleukin-13 levels. These conditions include inflammatory conditions, asthma bronchiale, atopic dermatitis, allergies, atopic syndromes, allergic rhinitis, and th2-induced conditions.
A method for reducing Interleukin-4 (IL-4R) or Interleukin-13 (IL-13R) signaling in a cell or subject comprising administering an inhibitor of Rac/Pak driven endocytosis in an amount sufficient to reduce or inhibit endocytosis of IL-4R or IL-13R, wherein, the IL-4R or IL-13R signaling is associated with Rac/Pak driven endocytosis.
A method of treating a condition characterized by increased Interleukin-4 (IL-4R) or Interleukin-13 (IL-13R) levels in a subject in need thereof comprising administering an inhibitor of Rac/Pak driven endocytosis in a therapeutically effective amount, wherein, the increase in IL-4R or IL-13R levels is associated with Rac/Pak driven endocytosis.
A method of treating atopic dermatitis in a subject in need thereof comprising administering an inhibitor of Rac/Pak driven endocytosis in a therapeutically effective amount, wherein, the atopic dermatitis is associated with Rak/Pak driven endocytosis.
Dependencies are inferred from the claim text.